Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith Mitchell

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancerEric Van Cutsem, Cathy Eng, Elzbieta Nowara, et al.
Ethnicity & Disease|February 2, 2022
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical TrialsOwen Garrick, Ruben Mesa, Andrea Ferris, et al.
Targeted Oncology|December 27, 2015
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based TherapyEric Van Cutsem, Florence Joulain, Paulo M Hoff, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancerEric Van Cutsem, Cathy Eng, Elzbieta Nowara, et al.
Ethnicity & Disease|February 2, 2022
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical TrialsOwen Garrick, Ruben Mesa, Andrea Ferris, et al.
Targeted Oncology|December 27, 2015
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based TherapyEric Van Cutsem, Florence Joulain, Paulo M Hoff, et al.
Pageof 5